Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

Published Date: 07 Jun 2024

In the durvalumab group, the median OS was 55.9 months, while in the placebo group it was 33.4 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Universal screening approach achieves a comparable detection rate of lung cancer

2.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

3.

New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

4.

Stereotactic Radiation Linked to Better Brain Mets Outcomes

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot